EUVIMEDEUVIMED entdecken
Crossref

SOX9 siRNA Loaded Lipid Nanoparticles Actively Targeted: Formulation, Delivery, and Antitumor Effect on Colorectal Cancer In Vitro and In Vi vo

Zhen Zhang, Hongbo Wang, Zhijun Zhang, Yaoyao Zhang, Huajing Sun, Xi Chen, Jiayu Gu, Yanling Gong iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Zhen Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China. Hauptthemen laut MEDLINE: RNA, Small Interfering, Colorectal Neoplasms, Nanoparticles, SOX9 Transcription Factor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 76 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small interfering RNA (siRNA)-based therapy, which silences disease-associated genes, has emerged as a potential therapeutic strategy for various disorders, including cancer. Lipid nanoparticles (LNPs) have become a leading platform for efficient siRNA delivery. SOX9, a family member of SRY-related high-mobility-group box (SOX) transcription factors, plays an important role in the pathogenesis and progression of colorectal cancer (CRC). Here, we developed cRGDfK peptide-modificed LNPs (R-LNPs) composed of DLin-MC3-DMA, DMG-PEG, DSPC, DSPE-PEG-cRGDfK, and cholesterol for the targeted delivery of SOX9 siRNA (siSOX9) in CRC treatment. The formulation, delivery, and antitumor effect on CRC in vitro and in vivo were explored. The optimized R-LNPs exhibited favorable physicochemical properties including a uniform particle size (159.6 ± 0.93 nm), low polydispersity index (PDI = 0.207 ± 0.016), near-neutral zeta potential (2.74 ± 0.35 mV), and high encapsulated efficiency (90.71 ± 1.63%). Additionally, R-LNPs demonstrated sustained and controlled in vitro release and good serum stability. The prepared R-LNPs were efficiently uptaken by HCT-116 via clathrin, lipid rafts, and caveolae dependent endocytosis and macropinocytosis. Subsequently, R-LNPs were colocalized with lysosomes before escaping into the cytoplasm, ensuring effective siRNA release. In vivo distribution studies confirmed tumor-specific accumulation for R-LNPs in HCT-116 xenograft models. Functionally, R-LNPs loading siSOX9 inhibited the proliferation, migration, and invasion of HCT-116 cells and Caco-2 cells (P < 0.05 or 0.01) and inhibited tumor growth and proliferation in tumor-bearing mice (P < 0.05 or 0.01). The antitumor effects were attributed to the silence of SOX9, which subsequently downregulated key oncogenic mediators, including β-catenin, cyclin D1, and c-Myc (P < 0.05 or 0.01). Furthermore, R-LNPs demonstrated favorable safety in in vivo application. In conclusion, our cRGDfK-modified LNPs loading siSOX9 represent a promising targeted therapeutic strategy for CRC, offering both efficacy and biocompatibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Small InterferingColorectal NeoplasmsNanoparticlesSOX9 Transcription FactorLipidsHumansAnimalsMiceXenograft Model Antitumor AssaysMice, NudeCell Line, TumorMice, Inbred BALB CHCT116 CellsParticle SizeLiposomes

Stichwörter der Autor:innen

SOX9cRGDfKcolorectal cancerlipid nanoparticlessiRNA

Substanzen

RNA, Small InterferingSOX9 Transcription FactorSOX9 protein, humanLipidsLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
  • Department of Gastrointestinal Surgery, the People's Hospital of Jimo, Qingdao 266200, China.
  • Department of Physiology, School of Basic Medicine, Qingdao University, Qingdao 266073, China.
  • Department of Pharmacy, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China.

ORCID-Profile: Yanling Gong

Zitieren

APA

Zhang, Z., Wang, H., Zhang, Z., Zhang, Y., Sun, H., Chen, X., Gu, J., & Gong, Y. (2025). SOX9 siRNA Loaded Lipid Nanoparticles Actively Targeted: Formulation, Delivery, and Antitumor Effect on Colorectal Cancer In Vitro and In Vi vo. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00272

Vancouver

Zhang Z, Wang H, Zhang Z, Zhang Y, Sun H, Chen X, et al. SOX9 siRNA Loaded Lipid Nanoparticles Actively Targeted: Formulation, Delivery, and Antitumor Effect on Colorectal Cancer In Vitro and In Vi vo. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00272

BibTeX
@article{Zhang2025,
  author = {Zhang, Zhen and Wang, Hongbo and Zhang, Zhijun and Zhang, Yaoyao and Sun, Huajing and Chen, Xi and Gu, Jiayu and Gong, Yanling},
  title = {SOX9 siRNA Loaded Lipid Nanoparticles Actively Targeted: Formulation, Delivery, and Antitumor Effect on Colorectal Cancer In Vitro and In Vi vo},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00272}
}
Kostenlos starten →